Amgen Inc. with ticker code (AMGN) have now 22 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $380.00 and $185.00 calculating the mean target share price we have $305.41. (at the time of writing). Given that the stocks previous close was at $295.87 this now indicates there is a potential upside of 3.2%. There is a 50 day moving average of $293.39 while the 200 day moving average is $259.36. The company has a market capitalization of 157.80B. The stock price for the company is currently $294.85 USD
The potential market cap would be $162,885,233,621 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 23.63, revenue per share of $52.69 and a 10.32% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
